| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | 2PP2A; IGAAD; TAF-I; I2PP2A; IPP2A2; PHAPII; TAF-IBETA |
| Entrez GeneID | 6418 |
| WB Predicted band size | Calculated MW: 33 kDa; Observed MW: 39 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human SET |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于SET抗体的3篇示例参考文献(内容为模拟，非真实文献)：
---
1. **文献名称**：*"SET Protein as a Therapeutic Target in Alzheimer's Disease: Role in Tau Hyperphosphorylation"*
**作者**：Chen L. et al.
**摘要**：研究揭示了SET蛋白通过抑制蛋白磷酸酶PP2A加剧tau蛋白的异常磷酸化，促进阿尔茨海默病进展。使用特异性SET抗体阻断其功能后，可恢复PP2A活性并减少神经病理损伤，提示其作为潜在治疗靶点。
---
2. **文献名称**：*"Oncogenic Role of SET in Acute Myeloid Leukemia: Mechanisms and Antibody-Based Inhibition"*
**作者**：Rodriguez-Perez J. et al.
**摘要**：本研究发现SET蛋白在急性髓系白血病(AML)中过表达，通过表观遗传调控促进细胞增殖和化疗耐药。开发的人源化SET抗体在体外和小鼠模型中显著抑制肿瘤生长，为靶向SET的癌症治疗提供新策略。
---
3. **文献名称**：*"Autoantibodies Against SET in Systemic Lupus Erythematosus: Clinical Correlations and Pathogenic Implications"*
**作者**：Kim S. et al.
**摘要**：该研究在系统性红斑狼疮(SLE)患者血清中检测到高水平的抗SET自身抗体，并与疾病活动度正相关。实验表明抗SET抗体可能通过干扰DNA修复通路加剧自身免疫反应，提出其作为SLE诊断标志物的潜力。
---
**注**：以上文献为示例性内容，实际引用时需以真实发表的论文为准。
SET antibodies target the SET protein, a multifunctional oncoprotein implicated in epigenetic regulation and cancer progression. The SET gene, initially identified in acute undifferentiated leukemia as part of the SET-NUP214 fusion protein, encodes a chromatin-binding protein that modulates histone modification. Structurally, SET contains conserved domains (e.g., N-terminal dimerization, acidic, and C-terminal regions) enabling interactions with histone chaperones, transcription factors, and signaling molecules. Functionally, SET inhibits protein phosphatase 2A (PP2A), a tumor suppressor phosphatase, thereby promoting hyperactivation of oncogenic pathways (e.g., AKT, ERK). Its overexpression correlates with cellular proliferation, apoptosis resistance, genomic instability, and metastasis in various cancers (e.g., leukemia, breast, lung).
SET antibodies are critical tools for studying its expression, localization, and mechanistic roles in cancer biology. They are utilized in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess SET levels in clinical samples or experimental models. Additionally, SET-targeting therapeutic antibodies or inhibitors are under exploration to restore PP2A activity and suppress tumor growth. However, challenges remain, including isoform-specific detection (due to multiple splice variants) and distinguishing functional versus non-functional SET pools. Research continues to clarify its context-dependent roles in DNA repair, stemness, and immune evasion, expanding its potential as a diagnostic biomarker or therapeutic target.
×
